BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/15/2024 9:49:52 AM | Browse: 311 | Download: 919
Publication Name World Journal of Diabetes
Manuscript ID 92506
Country Australia
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Editorial
Article Title Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards
Manuscript Source Invited Manuscript
All Author List Michael Horowitz, Lu Cai and Md Shahidul Islam
ORCID
Author(s) ORCID Number
Michael Horowitz http://orcid.org/0000-0002-0942-0306
Lu Cai http://orcid.org/0000-0003-3048-1135
Md Shahidul Islam http://orcid.org/0000-0003-0309-9491
Funding Agency and Grant Number
Corresponding Author Michael Horowitz, DSc, FRACP, MBBS, PhD, Director, Director, Professor, Department of Medicine, University of Adelaide, Level 5, AHMS Corner North Tce and George St, Adelaide 5005, Australia. michael.horowitz@adelaide.edu.au
Key Words Glucagon-like-peptide-1; Glucose-dependent insulinotropic peptide; Gastric emptying; Type 2 diabetes
Core Tip In people who are prescribed a glucagon-like-peptide-1 receptor agonist (GLP-1RA) for management of type 2 diabetes or obesity you should always ask about gastrointestinal symptoms both before and after initiating therapy. Gastrointestinal adverse effects of GLP-1RAs are common, but may not be volunteered.
Publish Date 2024-03-15 09:49
Citation Horowitz M, Cai L, Islam MS. Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards. World J Diabetes 2024; 15(3): 326-330
URL https://www.wjgnet.com/1948-9358/full/v15/i3/326.htm
DOI https://dx.doi.org/10.4239/wjd.v15.i3.326
Full Article (PDF) WJD-15-326-with-cover.pdf
Full Article (Word) WJD-15-326.docx